The quest for alternative drugs to the well-known cisplatin and its derivatives, which are still
used in more than 50% of the treatment regimes for patients suffering from cancer, is highly …

This review focuses on cytotoxic rhenium compounds in terms of IC 50 values, their mode of
action in biological systems and their status in clinical trials. Biological studies of different …

In the recent years, organometallic compounds have become recognized as promising anti-
cancer drug candidates. While radioactive 186/188Re compounds are already used in …

Our work has shown that certain ruthenium (II) arene complexes exhibit promising
anticancer activity in vitro and in vivo. The complexes are stable and water-soluble, and their …

Over the recent years, several Re (I) organometallic compounds have been shown to be
toxic to various cancer cell lines. However, these compounds lacked sufficient selectivity …

Combination therapy targeting both tumor growth and vascularization is considered to be a
cornerstone for colorectal carcinomas (CRC) treatment. However, the major obstacles of …

Rhenium (V) oxo complexes of general formula [ReO (OMe)(N^ N) Cl2], where N^ N= 4, 7-
diphenyl-1, 10-phenanthroline, 1, or 3, 4, 7, 8-tetramethyl-1, 10-phenanthroline, 2, effectively …

By virtue of their favorable properties, rhenium (I) tricarbonyl (Re (CO) 3) complexes have
arisen as novel therapeutic agents and cellular imaging probes for addressing problems of …

The synthesis, characterization, in vitro imaging, and cytotoxic properties of a new folate
conjugate of rhenium (I) are reported. The conjugate [FA‐PEG‐BQAV‐Re (CO) 3]+(γ‐4) was …

The photophysical properties of [Re (CO) 3 (l‐N3)] Br (l‐N3= 2‐azido‐N, N‐bis [(quinolin‐2‐
yl) methyl] ethanamine), which could not be localized in cancer cells by fluorescence …